Klinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.
EuroIntervention. 2013 May;9 Suppl R:R54-7. doi: 10.4244/EIJV9SRA10.
Catheter-based renal denervation (RDN) leads to a considerable decrease of blood pressure in the vast majority of patients with resistant hypertension. However, only minor or no blood pressure change is achieved in some patients. This non-reponse is defined as a reduction of office systolic blood pressure of less than 10 mmHg following RDN. The rates of non-response vary between 8-37%. Here several causes are discussed such as inappropriate patient selection, an ineffective procedure, the subordinate contribution of sympathetic activation for the maintenance of hypertension, and patient conditions such as non-adherence to drug therapy. Based on current evidence, an ideal candidate for RDN has high baseline blood pressure, which is known to be the best predictor for blood pressure reduction after RDN. In order to ensure treatment success further criteria have to be fulfilled, such as exclusion of secondary hypertension and optimised medical therapy.
经导管去肾神经术(RDN)可使绝大多数难治性高血压患者的血压显著下降。然而,在一些患者中,血压变化很小或无变化。这种无反应定义为 RDN 后诊室收缩压降低小于 10mmHg。无反应的发生率在 8-37%之间。这里讨论了几个原因,如不合适的患者选择、无效的手术、交感神经激活对维持高血压的次要贡献,以及患者的情况,如不遵医嘱进行药物治疗。基于目前的证据,RDN 的理想候选者具有较高的基线血压,这是 RDN 后血压降低的最佳预测指标。为了确保治疗成功,还必须满足其他标准,如排除继发性高血压和优化药物治疗。